|

Zimberelimab Clinical Trials

11 actively recruiting trials across 7 locations

▼ -1 trial since August 2026

Also known as: AB 122, AB-122, AB122, Anti-PD-1 Monoclonal Antibody GLS-010, GLS 010 +8 more

Pipeline

Phase 1: 4Phase 2: 4Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Tang-Du Hospital1
  • Taiho Pharmaceutical Co., Ltd.1
  • RemeGen Co., Ltd.1
  • Jonsson Comprehensive Cancer Center1
  • H. Lee Moffitt Cancer Center and Research Institute1

Indications

  • Cancer11
  • Cancer, Malignant Tumors1
  • Metastatic Cholangiocarcinoma1
  • Locally Advanced Cholangiocarcinoma1
  • Metastatic Pancreatic Adenocarcinoma1

Other4 trials

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Phase 2
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Phase 3
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Phase 3
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Phase 2

Birmingham, Alabama1 trial

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Research Site

Phase 1

Los Angeles, California1 trial

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1

Palo Alto, California1 trial

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Stanford Cancer Center

Phase 1

New Haven, Connecticut1 trial

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Yale- New Haven Hospital- Yale Cancer Center

Phase 1

Tampa, Florida1 trial

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Moffitt Cancer Center

Phase 1/2

Boston, Massachusetts1 trial

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Beth Israel Deaconess Medical Center

Phase 2

New York, New York1 trial

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.